UK-based wound care firm Crawford Healthcare has received calls to fast-track its new wound dressing KerraCel Ag into the National Health Service (NHS).

KerraCel Ag is a thin, absorbent, gelling dressing with a silver technology called Ag Oxysalts that is developed and commercialised by Crawford in partnership with Canadian firm Exciton Technologies and the University of Manchester in the UK.

Designed to disrupt and kill antimicrobial biofilms, the dressing secured approval from the US Food and Drug Administration (FDA) in February.

KerraCel Ag is said to have achieved a breakthrough in diabetic foot ulcers treatment, as it was responsible for the prevention of amputation in 47-year old American patient, Angela Montes de Oca.

“Angela was fully recovered within eight weeks following the use of the KerraCel Ag dressing.”

Angela was fully recovered within eight weeks following the use of the KerraCel Ag dressing.

Based on this achievement, the dressing, which is currently available only in the US, is being called for deployment in the UK’s NHS and various other international healthcare systems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Crawford Healthcare CEO Richard Anderson said: “To provide some context on the significance of Ms Montes de Oca’s successful treatment, every single day in England there are 20 devastating amputations, with total expenditure related to foot amputation in people with diabetes in England estimated to be £1bn per year.

“With such an early success for KerraCel Ag, however, and against the cost in both surgery fees and devastation that is caused to people’s lives through amputation, we are looking to fast track this new treatment into NHS pathways as soon as feasibly possible.”

Image: KerraCel Ag is the first FDA-cleared absorbent gelling dressing containing Oxysalt technology. Photo: courtesy of Crawford Healthcare.